FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017218082> ?p ?o ?g. }

• W2017218082 endingPage "275" @default.
• W2017218082 startingPage "264" @default.
• W2017218082 abstract "Objective.—To investigate the efficacy, tolerability, and safety of rofecoxib and ibuprofen for acute migraine treatment. Background.—Rofecoxib was effective and well tolerated in a previous study of treatment of a single migraine attack. We sought to replicate these findings for a single attack and also study the clinical profile of rofecoxib in the acute treatment of multiple migraine attacks. Ibuprofen was included as a reference nonselective NSAID. Methods.—Adult migraineurs (n = 783) treated one migraine attack with either rofecoxib (25 or 50 mg), ibuprofen 400 mg, or placebo in a randomized, double‐blind study. Patients could elect to enroll in a 3‐month double‐blind extension phase. Results.—In the single‐attack phase, headache relief at 2 hours postdose was reported by 59.4%, 62.2%, and 57.7% of patients who took rofecoxib 25 mg, rofecoxib 50 mg, and ibuprofen 400 mg, respectively, versus 30.5% for placebo (all P < .001 vs placebo). The active drugs were statistically superior to placebo on a variety of additional measures. In the extension phase, the mean percentage of patients' attacks with headache relief at 2 hours postdose was 61.8% for rofecoxib 25 mg, 65.4% for rofecoxib 50 mg, and 59.3% for ibuprofen 400 mg. The mean percentage of patients' attacks with 24‐hour sustained headache relief was greater for rofecoxib 50 mg (52.0%) than for rofecoxib 25 mg (47.8%, P < .050) or ibuprofen (39.0%, P < .010). In the single‐attack phase, the adverse event rate was higher for rofecoxib 50 mg (37.8%) than placebo (27.8%, P < .050); rates were similar to placebo for rofecoxib 25 mg (32.0%, n.s.) and ibuprofen 400 mg (28.1%, n.s.). In the extension phase, treatment groups had similar adverse event rates. Conclusions.—Rofecoxib 25 and 50 mg and ibuprofen 400 mg were effective and generally well tolerated in the acute treatment of migraine." @default.
• W2017218082 created "2016-06-24" @default.
• W2017218082 creator A5006354448 @default.
• W2017218082 creator A5010276547 @default.
• W2017218082 creator A5014005812 @default.
• W2017218082 creator A5020485586 @default.
• W2017218082 creator A5021135644 @default.
• W2017218082 creator A5025640273 @default.
• W2017218082 creator A5038961547 @default.
• W2017218082 creator A5047308201 @default.
• W2017218082 creator A5057384130 @default.
• W2017218082 creator A5061230076 @default.
• W2017218082 creator A5069602047 @default.
• W2017218082 creator A5081765877 @default.
• W2017218082 date "2006-02-01" @default.
• W2017218082 modified "2023-10-16" @default.
• W2017218082 title "Rofecoxib in the Acute Treatment of Migraine: A Randomized Controlled Clinical Trial" @default.
• W2017218082 cites W1972160955 @default.
• W2017218082 cites W1996353828 @default.
• W2017218082 cites W2000795486 @default.
• W2017218082 cites W2014990551 @default.
• W2017218082 cites W2018863103 @default.
• W2017218082 cites W2031961111 @default.
• W2017218082 cites W2035663495 @default.
• W2017218082 cites W2044292672 @default.
• W2017218082 cites W2044750065 @default.
• W2017218082 cites W2053196807 @default.
• W2017218082 cites W2059830154 @default.
• W2017218082 cites W2134229174 @default.
• W2017218082 cites W2138361936 @default.
• W2017218082 cites W2145581220 @default.
• W2017218082 cites W2150491578 @default.
• W2017218082 cites W2158131645 @default.
• W2017218082 cites W2166530830 @default.
• W2017218082 cites W2167861291 @default.
• W2017218082 doi "https://doi.org/10.1111/j.1526-4610.2006.00334.x" @default.
• W2017218082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16492236" @default.
• W2017218082 hasPublicationYear "2006" @default.
• W2017218082 type Work @default.
• W2017218082 sameAs 2017218082 @default.
• W2017218082 citedByCount "29" @default.
• W2017218082 countsByYear W20172180822013 @default.
• W2017218082 countsByYear W20172180822014 @default.
• W2017218082 countsByYear W20172180822015 @default.
• W2017218082 countsByYear W20172180822016 @default.
• W2017218082 countsByYear W20172180822017 @default.
• W2017218082 countsByYear W20172180822022 @default.
• W2017218082 crossrefType "journal-article" @default.
• W2017218082 hasAuthorship W2017218082A5006354448 @default.
• W2017218082 hasAuthorship W2017218082A5010276547 @default.
• W2017218082 hasAuthorship W2017218082A5014005812 @default.
• W2017218082 hasAuthorship W2017218082A5020485586 @default.
• W2017218082 hasAuthorship W2017218082A5021135644 @default.
• W2017218082 hasAuthorship W2017218082A5025640273 @default.
• W2017218082 hasAuthorship W2017218082A5038961547 @default.
• W2017218082 hasAuthorship W2017218082A5047308201 @default.
• W2017218082 hasAuthorship W2017218082A5057384130 @default.
• W2017218082 hasAuthorship W2017218082A5061230076 @default.
• W2017218082 hasAuthorship W2017218082A5069602047 @default.
• W2017218082 hasAuthorship W2017218082A5081765877 @default.
• W2017218082 hasConcept C126322002 @default.
• W2017218082 hasConcept C142724271 @default.
• W2017218082 hasConcept C181199279 @default.
• W2017218082 hasConcept C185592680 @default.
• W2017218082 hasConcept C197934379 @default.
• W2017218082 hasConcept C204787440 @default.
• W2017218082 hasConcept C27081682 @default.
• W2017218082 hasConcept C2778375690 @default.
• W2017218082 hasConcept C2778541695 @default.
• W2017218082 hasConcept C2778582115 @default.
• W2017218082 hasConcept C2779689624 @default.
• W2017218082 hasConcept C2779944601 @default.
• W2017218082 hasConcept C42219234 @default.
• W2017218082 hasConcept C55493867 @default.
• W2017218082 hasConcept C71924100 @default.
• W2017218082 hasConcept C98274493 @default.
• W2017218082 hasConceptScore W2017218082C126322002 @default.
• W2017218082 hasConceptScore W2017218082C142724271 @default.
• W2017218082 hasConceptScore W2017218082C181199279 @default.
• W2017218082 hasConceptScore W2017218082C185592680 @default.
• W2017218082 hasConceptScore W2017218082C197934379 @default.
• W2017218082 hasConceptScore W2017218082C204787440 @default.
• W2017218082 hasConceptScore W2017218082C27081682 @default.
• W2017218082 hasConceptScore W2017218082C2778375690 @default.
• W2017218082 hasConceptScore W2017218082C2778541695 @default.
• W2017218082 hasConceptScore W2017218082C2778582115 @default.
• W2017218082 hasConceptScore W2017218082C2779689624 @default.
• W2017218082 hasConceptScore W2017218082C2779944601 @default.
• W2017218082 hasConceptScore W2017218082C42219234 @default.
• W2017218082 hasConceptScore W2017218082C55493867 @default.
• W2017218082 hasConceptScore W2017218082C71924100 @default.
• W2017218082 hasConceptScore W2017218082C98274493 @default.
• W2017218082 hasIssue "2" @default.
• W2017218082 hasLocation W20172180821 @default.
• W2017218082 hasLocation W20172180822 @default.
• W2017218082 hasOpenAccess W2017218082 @default.
• W2017218082 hasPrimaryLocation W20172180821 @default.
• W2017218082 hasRelatedWork W1880393460 @default.

• next